• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Edesa Biotech Inc.

    5/31/24 5:01:09 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email
    S-8 1 edsa_s8.htm FORM S-8 edsa_s8.htm

    As filed with the Securities and Exchange Commission on May 31, 2024

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    EDESA BIOTECH, INC.

    (Exact name of registrant as specified in its charter)

     

    British Columbia, Canada

     

    N/A

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     

     

     

    100 Spy Court

    Markham, Ontario, Canada

     

    L3R 5H6

    (Address of principal executive offices)

     

    (Zip Code)

     

    Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

    (Full title of the plan)

     

    Stephen Lemieux

    Chief Financial Officer

    c/o Edesa Biotech, Inc.

    100 Spy Court

    Markham, Ontario, Canada L3R 5H6

    (Name and address of agent for service)

     

    (289) 800-9600

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Steven M. Skolnick, Esq.

    Michael J. Lerner, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Smaller reporting company

    ☒

    Non-accelerated filer

    ☒

    Accelerated filer

    ☐

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is filed by Edesa Biotech, Inc., a British Columbia corporation (the “Registrant”), relating to 67,000 common shares, no par value per share (the “Common Shares”), issuable under the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (the “Plan”), which Common Shares are in addition to (i) the 164,736 Common Shares registered on the Registrant’s Form S-8 filed on January 28, 2020 (Registration No. 333-236121), (ii) the 213,858 Common Shares registered on the Registrant’s Form S-8 filed on April 23, 2021 (Registration No. 333-255485), and (iii) the 197,143 Common Shares registered on the Registrant’s Form S-8 filed on May 24, 2023 (Registration No. 333-272176) (collectively, the “Prior Registration Statements”).

     

    This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

     All share amounts referenced above and otherwise in this Registration Statement give effect to a 1-for-7 reverse split of the Common Shares effected on October 11, 2023.

     

     
    2

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents, which previously have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein and shall be deemed to be a part hereof:

     

     

    ·

    our Annual Report on Form 10-K for our fiscal year ended September 30, 2023 (filed on December 15, 2023);

     

     

     

     

    ·

    our Quarterly Reports on Form 10-Q for our fiscal quarters ended December 31, 2023 (filed on February 9, 2024) and March 31, 2024 (filed on May 10, 2024);

     

     

     

     

    ·

    our Current Reports on Form 8-K, dated October 10, 2023 (filed on October 11, 2023); dated October 12, 2023 (filed on October 12, 2023), dated October 20, 2023 (filed on October 23, 2023); dated October 25, 2023 (filed on October 26, 2023) and May 30, 2024 (filed on May 30, 2024); and

     

     

     

     

    ·

    the description of our Common Shares contained in our Registration Statement on Form 8-A filed with the SEC on November 3, 2015, including any amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. The Registrant’s file number with the Commission is No. 001-37619.

     

     
    3

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement:

     

    Exhibit

    Number

     

     

    Incorporated by Reference

     

     

     

     

    Filed

    Herewith

     

    Exhibit Description

     

    Form

     

    File Number

     

    Exhibit

     

    Filing Date

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    5.1

     

    Opinion of Fasken Martineau Dumoulin LLP

     

     

     

     

     

     

     

     

     

    X

    10.1

     

    Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

     

    8-K

     

    001-37619

     

    10.1

     

    10/25/2019

     

     

    10.2

     

    Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

     

    8-K

     

    001-37619

     

    10.1

     

    4/23/2021

     

     

    10.3

     

    Amendment No. 2 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

     

    8-K

     

    001-37619

     

    10.1

     

    5/24/2023

     

     

    10.4

     

    Amendment No. 3 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

     

    8-K

     

    001-37619

     

    10.1

     

    5/30/2024

     

     

    23.1

     

    Consent of Fasken Martineau Dumoulin LLP (included in Exhibit 5.1)

     

     

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney (included on signature page)

     

     

     

     

     

     

     

     

     

    X

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

    X

     

     
    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Markham, Province of Ontario, on May 31, 2024.

     

    EDESA BIOTECH, INC.

     

     

     

     

     

     

    By:

    /s/ Pardeep Nijhawan

     

     

     

    Pardeep Nijhawan

     

     

     

    Director, Chief Executive Officer and Corporate Secretary

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Pardeep Nijhawan and Stephen Lemieux, and each of them, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Pardeep Nijhawan

     

    Director, Chief Executive Officer and Corporate Secretary

     

    May 31, 2024

    Pardeep Nijhawan

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Stephen Lemieux

     

    Chief Financial Officer

     

    May 31, 2024

    Stephen Lemieux

     

    (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    /s/ Joan Chypyha

     

    Director

     

    May 31, 2024

    Joan Chypyha

     

     

     

     

     

     

     

     

     

    /s/ Sean MacDonald

     

    Director

     

    May 31, 2024

    Sean MacDonald

     

     

     

     

     

     

     

     

     

    /s/ Patrick Marshall

     

    Director

     

    May 31, 2024

    Patrick Marshall

     

     

     

     

     

     

     

     

     

    /s/ Frank Oakes

     

    Director

     

    May 31, 2024

    Frank Oakes

     

     

     

     

     

     

     

     

     

    /s/ Charles Olson

     

    Director

     

    May 31, 2024

    Charles Olson

     

     

     

     

     

     

     

     

     

    /s/ Carlo Sistilli

     

    Chairman of the Board of Directors

     

    May 31, 2024

    Carlo Sistilli

     

     

     

     

     

     
    5

     

    Get the next $EDSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep was granted 11,168 shares, increasing direct ownership by 2% to 512,990 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    2/2/26 5:01:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 10,444 shares, increasing direct ownership by 2% to 501,822 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    1/5/26 9:00:34 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 8,766 shares, increasing direct ownership by 2% to 491,378 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    12/2/25 6:01:01 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edesa Biotech Reports Fiscal Year 2025 Results

    TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa's dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients with moderate-to-severe nonsegmental vitiligo. Edesa anticipates that recruitment will begin by midyear 2026, subject to the completion of clinical-grade drug manufacturing and regulatory approvals

    12/12/25 4:20:00 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Announces Upcoming Conference Schedule

    TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Vienna, Austria, November 3-5, 2025LSX Investival Showcase Europe, London, UK, November 17, 2025. Presentation at 3:45 pm GMT. To schedule a meeting with Edesa during the events, please contact conference organizers or the company directly at [email protected]. About Edesa Biotech, Inc. Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage

    10/31/25 4:30:00 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

    Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consistent safety and tolerability profile TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics (HDTs) for immuno-inflammatory diseases, today announced positive results from a Phase 3 study evaluating the company's drug candidate paridiprubart (EB05) as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respir

    10/28/25 7:45:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Nijhawan Pardeep bought $20,000 worth of shares (5,000 units at $4.00) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/25/24 7:00:59 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    SEC Filings

    View All

    Edesa Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Edesa Biotech, Inc. (0001540159) (Filer)

    12/12/25 4:45:26 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Edesa Biotech Inc.

    424B5 - Edesa Biotech, Inc. (0001540159) (Filer)

    12/12/25 4:40:32 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Edesa Biotech Inc.

    10-K - Edesa Biotech, Inc. (0001540159) (Filer)

    12/12/25 4:30:52 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

    HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

    12/20/21 6:08:21 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    View All

    Edesa Biotech Announces Chief Financial Officer Transition

    TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

    4/4/25 4:15:46 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

    TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

    6/27/23 8:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Strategy Expert to Board of Directors

    TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

    3/29/22 9:00:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

    SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

    11/1/24 8:50:52 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Edesa Biotech Inc.

    SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

    6/3/24 4:10:38 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

    SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

    1/29/24 4:29:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care